Complement biology is moving from theory to therapeutic target in rheumatology
Complement once sat at the edge of rheumatology, invoked mainly as a marker of immune complex disease. That view has changed. Translational work, biomarker studies, and animal models now place the complement cascade inside the inflammatory machinery of several rheumatic diseases, especially antineutrophil cytoplasmic antibody-associated vasculitis (AAV) and rheumatoid arthritis (RA). The most consistent signal points to the alternative pathway and downstream generation of C5a as a driver of tissue injury.
This matters because complement is not merely present in diseased tissue; it helps amplify leukocyte recruitment, vascular injury, and synovial inflammation. In practical terms, the pathway can convert an autoimmune trigger into sustained organ damage. For clinicians, that opens a distinct therapeutic logic: block the mediator early enough, and the inflammatory cascade may soften before steroids and cytotoxic drugs are forced to carry the full burden.
AAV trials gave the clearest proof of concept
Among rheumatologic diseases, AAV has offered the strongest clinical validation of complement blockade. Preclinical work showed activation of complement in affected tissues and blood, and murine models linked the alternative pathway to target-organ damage. The central mechanism converged on C5a, a potent anaphylatoxin that recruits and primes myeloid cells, intensifying vascular inflammation.
A novel oral C5aR1 antagonist changed the discussion. Clinical trials in AAV showed a substantial corticosteroid-sparing effect, along with early evidence of clinical benefit. The steroid-sparing component is especially important in vasculitis, where cumulative glucocorticoid exposure often drives much of the downstream toxicity, from infection risk to metabolic and skeletal complications. A targeted oral inhibitor that reduces the need for prolonged steroid exposure offers a mechanistically coherent way to improve disease control without relying on escalating glucocorticoid dose.
A single sentence captures the clinical shift: complement blockade in AAV moved from biologic plausibility to bedside relevance.
The pathophysiology also fits the clinical phenotype. AAV is defined by inflammatory injury to vessels, and the alternative pathway can magnify neutrophil activation at precisely the point where the vessel wall is most vulnerable. By interrupting C5a signaling, the therapy addresses a feed-forward loop rather than a downstream consequence. The trials therefore did more than demonstrate symptom improvement; they supported a biologically specific intervention against a defined inflammatory axis.
Rheumatoid arthritis has been harder to move with complement inhibition
RA tells a more complicated story. Biomarker studies and murine work strongly support complement involvement, and the biology is not in doubt. Synovial inflammation, immune activation, and local tissue injury all make complement an appealing target. Yet clinical intervention with C5 and C5aR1 inhibitors produced only modest benefit.
The gap between mechanism and outcome may reflect several possibilities. RA is biologically heterogeneous, and complement activation may be more prominent in some phenotypes than others. Timing also likely matters. If complement amplification is most relevant early in the inflammatory process, then treating established, chronic synovitis may come too late to achieve a dramatic clinical effect. A second possibility is target selection: blocking C5 or C5aR1 may not fully suppress the relevant inflammatory nodes in RA, where multiple parallel immune pathways can sustain disease activity even when complement is dampened.
A single pathway did not overcome the complexity of rheumatoid arthritis.
This is not a failure of the biology. It is a reminder that pathogenic relevance and therapeutic leverage are not the same thing. RA may still depend on complement activity, but the disease may also require a different target, a different stage of intervention, or combination therapy to produce clinically meaningful change. In that sense, the modest signal in RA is informative. It narrows expectations and forces a more precise question: where, and in whom, does complement blockade matter enough to change the course of disease?
The broader rheumatic disease portfolio may hold additional targets
Beyond AAV and RA, many other diseases seen in rheumatology show evidence of complement activation in ways that may be pathogenic rather than incidental. The review places this broader field in context: complement is increasingly implicated across multiple inflammatory and immune-mediated syndromes, and the pathway’s involvement may differ by organ, tissue compartment, and disease stage. Some disorders may involve immune complex deposition, others tissue-specific complement activation, and others still a mixture of innate and adaptive immune amplification.
For practicing rheumatologists, this creates both opportunity and caution. Opportunity comes from the expanding list of candidate diseases in which complement could become a therapeutic target. Caution comes from the fact that complement is not a single switch. Different nodes in the cascade have different effects, and clinical benefit will likely depend on selecting the right node for the right disease biology. A proximal inhibitor may be appropriate in one setting, while a distal antagonist such as a C5a pathway blocker may be better suited in another.
The review also makes clear that biomarker work remains central. Tissue activation and blood-based signatures help define whether complement is truly involved and may identify the patients most likely to respond. Without that enrichment, trials risk diluting a treatment effect across a biologically mixed population.
What the current evidence means for rheumatology practice
The clearest lesson from the current complement literature is not that one drug class will work across autoimmune disease. It is that complement is a legitimate disease driver in some rheumatic disorders and a partial contributor in others. AAV currently offers the most persuasive proof that targeting the C5a–C5aR1 axis can produce meaningful clinical benefit, especially when steroid sparing is a major goal. RA, by contrast, has shown that strong preclinical rationale does not guarantee large therapeutic gains once the disease becomes established in humans.
That divergence should shape future trial design. Better biomarker selection, earlier intervention, and more disease-specific target choice are the most plausible routes forward. The review stops short of claiming that complement inhibition has solved rheumatology. It has not. What it does show is that the pathway has earned a serious place in the therapeutic discussion, particularly where inflammation is driven by vascular injury and myeloid activation.
The remaining question is not whether complement matters in rheumatic disease. It does. The harder question is which diseases, which patients, and which point in the inflammatory course will yield a real clinical payoff from blocking it.